Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

9 Sep 2019
Company, THR-149
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
  • Immediate onset of action - starting from Day 1 with increasing average
    • ...
5 Sep 2019
Company, Investors
Oxurion NV Business Update – H1 2019

Positive Topline Phase 1 Results with THR-149 (Plasma Kallikrein...

4 Sep 2019
THR-687
Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)

Company on Track for Data Read Out by End of 2019...

2 Sep 2019
THR-149, THR-317, THR-687
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019

Further preclinical and clinical data presentations of its...

20 Aug 2019
THR-317
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
  • Combination therapy did not show increase in BCVA in the overall population at Month 3.
    • ...
1 Jul 2019
THR-149
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
  • Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or
    • ...
11 Jun 2019
Company
ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies

Leuven, Belgium 11 June 2019 – ONCURIOUS NV, a Belgium-based biotech company...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all relevant stakeholders. Regarding any press enquiries, comments or questions about Oxurion, please contact our Corporate Communications department:

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com

Media Center

Easy accessible and always available, the Oxurion Media Center is your access point for Oxurion related AV assets. Feel free to register and download any material you may need.

Oxurion Media Center

The materials (such as images, photographs, illustrations, icons, texts, video clips, written and other proprietary information) contained in this Media Center (the “Materials”) are the valuable property of Oxurion NV and/or its licensors. Oxurion and/or its licensors, as appropriate, reserve all patent, copyright and other proprietary rights to the Materials, including all design, manufacturing, reproduction, use, and sales rights thereto. You may download, print and use the Materials solely for the permitted purpose as specified in the respective “Asset Details” or – if Oxurion provides you with a download link – for any purpose, provided you do not delete or change any copyright or trademark, or distort, mutilate or otherwise modify the proprietary information in a manner that may be prejudicial to Oxurion or its licensors. To allow for design, content and specification improvements, the Materials in this Media Center are subject to change at any time, without notice. Reproduction of this Media Center or portions thereof without prior written approval of Oxurion is prohibited.